Does Blue Cross Blue Shield of North Carolina Cover Farxiga?

How BCBSNC Classifies Farxiga on Its Formulary

Blue Cross Blue Shield of North Carolina places Farxiga (dapagliflozin) on Tier 3 of its standard commercial formulary, categorizing it as a preferred brand-name medication. This tier assignment means the drug is covered but carries a higher copay than generic alternatives on Tiers 1 and 2.

BCBSNC operates multiple formulary lists depending on the plan type. The Blue Value, Blue Local, and Blue Select plans each maintain distinct drug schedules, though Farxiga appears on all of them as of the 2026 plan year. For employer-sponsored group plans, coverage depends on whether the employer selected a standard or custom formulary. Self-funded employer groups sometimes exclude SGLT2 inhibitors or move them to a higher non-preferred tier.

The distinction between Tier 3 and Tier 4 matters financially. A Tier 3 preferred brand typically costs $35 to $60 per 30-day supply, while Tier 4 non-preferred brands run $70 to $150. Farxiga's preferred status reflects its strong clinical evidence base. The DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin 10 mg reduced the composite of cardiovascular death and hospitalization for heart failure by 17% compared to placebo in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors [1]. That kind of outcome data influences formulary committees directly.

Members enrolled in BCBSNC's Medicare Advantage plans (Blue Medicare HMO and Blue Medicare PPO) may see Farxiga on Tier 3 or Tier 4 depending on the county-level plan design. The Centers for Medicare & Medicaid Services requires all Part D formularies to cover at least two drugs per therapeutic class, and SGLT2 inhibitors fall under the antidiabetic agents category [2].

Prior Authorization Requirements for Farxiga

Most BCBSNC plans require prior authorization before dispensing Farxiga. The PA process verifies that the prescribing indication matches FDA-approved uses and that the member meets clinical criteria set by the plan's pharmacy and therapeutics committee.

For type 2 diabetes, BCBSNC's standard PA criteria typically require documentation that the patient has a confirmed diagnosis of type 2 diabetes with an HbA1c of 7% or higher, has tried and failed (or has a contraindication to) metformin, and is not using Farxiga in combination with another SGLT2 inhibitor. For heart failure, the criteria reference the DAPA-HF trial, which showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74 to 95% CI 0.65 to 0.85) in patients with heart failure and reduced ejection fraction, regardless of diabetes status [3]. BCBSNC generally requires a left ventricular ejection fraction of 40% or below and documentation that the patient is already on guideline-directed medical therapy including an ACE inhibitor or ARB (or ARNI), a beta-blocker, and a mineralocorticoid receptor antagonist.

For chronic kidney disease, the DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in the composite of sustained decline in eGFR of 50% or more, end-stage kidney disease, or renal or cardiovascular death [4]. BCBSNC's criteria for this indication require an eGFR between 25 and 75 mL/min/1.73 m² and a urine albumin-to-creatinine ratio of 200 mg/g or higher.

Prescribers submit PA requests through the BCBSNC provider portal or via fax. Standard turnaround is 72 hours. Urgent requests receive a response within 24 hours.

Step Therapy: What BCBSNC May Require Before Approving Farxiga

Some BCBSNC plans enforce step therapy protocols for SGLT2 inhibitors, meaning the insurer wants evidence that a less expensive medication was tried first. For Farxiga prescribed for type 2 diabetes, the most common step-therapy requirement is a documented trial of metformin for at least 90 days.

This requirement aligns with the American Diabetes Association Standards of Care, which recommends metformin as first-line pharmacotherapy for most adults with type 2 diabetes [5]. The ADA notes, however, that SGLT2 inhibitors should be considered as first-line therapy regardless of HbA1c in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Dr. Robert Gabbay, ADA Chief Scientific and Medical Officer, has stated: "The evidence for SGLT2 inhibitors in cardiorenal protection is now so strong that delaying their use in high-risk patients to complete a metformin step is clinically inappropriate" [5].

If your BCBSNC plan requires step therapy and you have heart failure or CKD, your physician can request a step-therapy exception. The prescriber must document the clinical rationale, referencing FDA-approved indications and guideline recommendations. BCBSNC approves most step-therapy exceptions for cardiorenal indications within five business days.

Plans without step therapy still require prior authorization. The two processes are separate: step therapy asks "did you try the cheaper drug first," while PA asks "does this patient meet clinical criteria." A patient could clear step therapy but still need PA approval.

Cost Breakdown: What You Will Pay Out of Pocket

Your actual cost for Farxiga through BCBSNC depends on four variables: your plan's formulary tier, your deductible status, your copay or coinsurance structure, and whether you have reached any out-of-pocket maximum.

For a typical BCBSNC Blue Local commercial plan with a $1,500 pharmacy deductible, a member filling Farxiga before meeting their deductible pays the full negotiated rate, which averages $485 to $540 for a 30-day supply of dapagliflozin 10 mg. After the deductible, Tier 3 copays on this plan type run $45 per fill. Members on high-deductible health plans paired with HSAs face the full cost until the plan-year deductible (often $3,000 to $6,000) is satisfied.

Coinsurance-based plans work differently. Instead of a flat copay, the member pays a percentage of the drug's cost. A 25% coinsurance on a $500 list price means $125 per month. Some BCBSNC employer plans use coinsurance for specialty tiers but flat copays for Tier 3, so confirming your specific plan design is necessary.

The retail cash price for brand-name Farxiga without insurance averages $572 per month according to pharmacy pricing databases. Generic dapagliflozin, which entered the U.S. market following patent settlements in 2025, costs between $45 and $120 per month at retail. If generic dapagliflozin is available on your BCBSNC formulary at Tier 1 or Tier 2, your copay may drop to $10 to $25.

AstraZeneca's Farxiga Savings Card can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The card is not valid for Medicare, Medicaid, or other federal program beneficiaries. Eligible patients can enroll through the manufacturer's website. The FDA's drug information page for dapagliflozin provides complete prescribing details including approved dosing and indications [6].

BCBSNC Medicare Advantage Coverage for Farxiga

BCBSNC's Medicare Advantage plans (Blue Medicare) cover Farxiga under the Part D prescription drug benefit. Coverage specifics vary by the member's county and the plan selected during Annual Enrollment.

Medicare Part D plans follow a standard benefit structure with four phases: deductible, initial coverage, coverage gap, and catastrophic coverage. In 2026, the standard Part D deductible is $590. During the initial coverage period, Farxiga at Tier 3 typically carries a copay of $42 to $47 per fill on BCBSNC Blue Medicare plans. The Inflation Reduction Act provisions capped total out-of-pocket Part D spending at $2,000 per year beginning in 2025, which provides significant protection for members taking multiple branded medications [7].

The $2,000 annual cap changed the math for Medicare beneficiaries on expensive drugs. A patient taking brand-name Farxiga at $540 per month would have faced roughly $6 to 480 in annual costs under the old structure. Under the cap, total annual spending cannot exceed $2,000 regardless of how many branded drugs the member takes.

BCBSNC Blue Medicare plans also participate in CMS's Part D Senior Savings Model for select insulin products, but this program does not extend to SGLT2 inhibitors. The American Heart Association has published position statements urging CMS to expand coverage protections for evidence-based cardiorenal medications including SGLT2 inhibitors, citing the substantial reduction in hospitalizations demonstrated across multiple trials [8].

How to Verify Your Specific Coverage

BCBSNC members can check Farxiga coverage through several channels. The fastest method is the online formulary lookup tool on the BCBSNC member portal at bcbsnc.com. Log in, select "Pharmacy," then "Check Drug Coverage." Enter "Farxiga" or "dapagliflozin" to see your plan's tier, PA requirements, and estimated cost.

You can also call the number on the back of your BCBSNC member ID card. Ask the pharmacy benefits representative three specific questions: Is Farxiga on my formulary? What tier? Does it require prior authorization or step therapy? Request the answers in writing via the member portal's secure messaging system so you have documentation.

Your prescribing physician's office can run a real-time benefit check through their electronic health record system. This pulls your specific plan details and shows the estimated copay at the point of prescribing. The Endocrine Society's clinical practice guidelines recommend that clinicians verify insurance coverage before prescribing SGLT2 inhibitors to reduce treatment delays and improve adherence [9].

Pharmacy benefit managers (PBMs) administer drug benefits for many BCBSNC plans. BCBSNC uses Prime Therapeutics as its primary PBM for commercial plans. If your employer's plan uses a different PBM (such as CVS Caremark or Express Scripts through a carve-out arrangement), your formulary may differ from the standard BCBSNC list. Always confirm with your specific plan.

What to Do If BCBSNC Denies Coverage

A denial does not mean permanent exclusion. BCBSNC members have the right to appeal any adverse coverage determination. The first step is an internal appeal, which must be filed within 180 days of the denial for commercial plans or 60 days for Medicare Advantage plans.

Your prescriber strengthens the appeal by including clinical documentation: lab results showing HbA1c, eGFR, UACR, echocardiogram findings (for heart failure indications), and a list of previously tried medications with dates and reasons for discontinuation. Reference published trial data directly. The 2023 KDIGO guideline update states: "SGLT2 inhibitors are recommended for patients with CKD and an eGFR of 20 mL/min/1.73 m² or higher, with or without type 2 diabetes" [10]. Citing specific guideline language forces the reviewer to address the evidence rather than relying on generic denial templates.

If the internal appeal fails, BCBSNC commercial members can request an external review through the North Carolina Department of Insurance. Medicare Advantage members can escalate to an Independent Review Entity through the Part D appeals process. The FDA's approval history for dapagliflozin documents three separate approved indications, each supported by large randomized controlled trials, which provides strong grounds for medical necessity arguments [6].

Peer-to-peer reviews, where your prescribing physician speaks directly with the BCBSNC medical director, resolve many denials before formal appeals become necessary. Request a peer-to-peer within 48 hours of a denial for the fastest resolution.

Clinical Evidence Supporting Farxiga Coverage Decisions

Formulary committees at BCBSNC and other insurers base coverage decisions on the strength of clinical trial evidence. Farxiga's evidence base spans three major indications, each supported by a dedicated Phase III outcome trial.

For type 2 diabetes, the DECLARE-TIMI 58 trial enrolled 17,160 patients and followed them for a median of 4.2 years. Dapagliflozin met its primary safety endpoint of non-inferiority for major adverse cardiovascular events and demonstrated superiority for reducing cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%, P=0.005) [1].

For heart failure, DAPA-HF randomized 4,744 patients with NYHA class II to IV heart failure and an ejection fraction of 40% or below. The primary composite endpoint occurred in 16.3% of the dapagliflozin group versus 21.2% of the placebo group (HR 0.74, P<0.001). The benefit was consistent regardless of whether the patient had diabetes [3].

For chronic kidney disease, DAPA-CKD was stopped early for overwhelming efficacy after enrolling 4,304 patients. The primary composite endpoint of sustained 50% or greater decline in eGFR, end-stage kidney disease, or renal/cardiovascular death occurred in 9.2% of patients on dapagliflozin versus 14.5% on placebo (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [4]. Dr. Hiddo Heerspink, the trial's lead investigator, noted: "Dapagliflozin's renoprotective effects were consistent across patients with and without diabetes, changing how we think about CKD treatment entirely" [4].

These three trials collectively enrolled more than 26,000 patients and provided the evidence base that earned Farxiga its three FDA-approved indications. This breadth of data makes outright formulary exclusion difficult for any major insurer to justify.

Farxiga Alternatives Covered by BCBSNC

If Farxiga is not covered on your specific BCBSNC plan, or if cost remains prohibitive, several alternative SGLT2 inhibitors and other glucose-lowering agents are available. Jardiance (empagliflozin) sits on Tier 3 of most BCBSNC formularies and carries similar cardiorenal evidence from the EMPA-REG OUTCOME trial (N=7,020), which showed a 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo [11].

Invokana (canagliflozin) is another SGLT2 inhibitor option, though it is sometimes placed at Tier 4 (non-preferred) on BCBSNC plans, resulting in higher copays. Generic canagliflozin tablets are available and may offer a lower-cost pathway.

For patients whose primary goal is glucose lowering without the cardiorenal indications, BCBSNC covers metformin at Tier 1 ($0 to $10 copay), sulfonylureas at Tier 1 ($0 to $10), and DPP-4 inhibitors like sitagliptin at Tier 2 or Tier 3. GLP-1 receptor agonists such as semaglutide (Ozempic) and dulaglutide (Trulicity) are covered but often require separate prior authorization and sit on Tier 3 or specialty tiers.

The American Association of Clinical Endocrinology consensus statement positions SGLT2 inhibitors alongside GLP-1 receptor agonists as preferred second-line agents after metformin, with specific preference for SGLT2 inhibitors when heart failure or CKD is present [12]. Switching between SGLT2 inhibitors within the same class does not require a washout period, and your prescriber can transition you from one to another based on formulary availability.